<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618965</url>
  </required_header>
  <id_info>
    <org_study_id>Pain relief for prostatictomy</org_study_id>
    <nct_id>NCT04618965</nct_id>
  </id_info>
  <brief_title>Intrathecal Versus Intravenous Dexmeditomedine in Transurethral Resection of the Prostate</brief_title>
  <official_title>The Effect of Intrathecal Versus Intravenous Dexmeditomedine on Postoperative Analgesia in Transurethral Resection of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate The analgesic effect of intrathecal versus intravenous&#xD;
      dexmeditomedine in transurethral resection of the prostate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will carried out in Tanta University hospital on75 male patients Patients will&#xD;
      randomly classified into 3 groups Group I: will receive intrathecal hyperbaric bupivacaine&#xD;
      10mg in 2.5 ml and .5 ml saline with 3ml total volume Group II: will receive dexmeditomedine&#xD;
      5Mic diluted in.5 ml saline and hyperbaric bupivacaine 10mg in 2.5ml with 3ml total volume&#xD;
      Group IIl: Will receive intravenous dexmeditomedine started at loading dose of 1 mic/kg&#xD;
      diluted in 50 ml saline and administered within 10 min as loading dose , followed by&#xD;
      maintenance at a dose of .4mic/kg/h diluted in200 ml saline till the end of surgery and&#xD;
      hyperbaric bupivacaine 10 mg in 2.5 ml total volume&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 26, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to first rescue analgesic</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>The duration between the administration of spinal block and the first desire for supplemental analgesia (onset of 1st post-operative analgesic dose).&#xD;
First post-operative analgesic dose will be1 μg/kg intravenous fentanyl when visual analogue pain score (VAS) is 4 or more</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score Total dose of analgesic consumption I the first postoperative day Intraoperative and postoperative complications</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Visual analogue score (VAS) between 0 and 10{0= no pain, 10=most severe pain}</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total analgesic consumption</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>The pain score will be assessed every 4 h in 24 h and fentanyl will be given in a dose of 1 μg /kg when Visual analogue score (VAS) is 4 or more. Any out breaking pain will be treated with increments of fentanyl in a dose of 0.5μg/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative and postoperative complications</measure>
    <time_frame>Intraoperative and 24 hours postoperative</time_frame>
    <description>e.g. hypotension, bradycardia and vomiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Transurethral Resection of Prostate</condition>
  <condition>Intravenous</condition>
  <condition>Intrathecal</condition>
  <arm_group>
    <arm_group_label>Control (Placebo) group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrathecal dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>Each patient will receive intrathecal hyperbaric bupivacaine 10 mg in 2.5 ml and 0.5 ml saline with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.</description>
    <arm_group_label>Control (Placebo) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal dexmedetomidine</intervention_name>
    <description>Each patient will receive dexmedetomidine 5 μg diluted in 0.5ml saline and hyperbaric Bupivacaine 10 mg in 2.5 ml with 3 mL total volume. Continous 50 ml saline infusion for 10 min followed by 200 ml saline infusion till the end of surgery.</description>
    <arm_group_label>Intrathecal dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous dexmedetomidine</intervention_name>
    <description>Each patient will receive intravenous dexmedetomidine started at a loading dose of 1 μg/kg diluted in 50 ml saline and administered within 10 min as a loading dose, followed by maintenance at a dose of 0.4 μg/kg/h diluted in 200 ml saline till the end of surgery and hyperbaric Bupivacaine 10 mg in 2.5 ml total volume.</description>
    <arm_group_label>Intravenous dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male gender&#xD;
&#xD;
          -  50:70years old&#xD;
&#xD;
          -  ASA:I,II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications of spinal anesthesia&#xD;
&#xD;
          -  Patient refusal&#xD;
&#xD;
          -  Patient taking alpha agonist or antagonist&#xD;
&#xD;
          -  Uncontrolled cardiac diseases&#xD;
&#xD;
          -  Allergy to local anesthetic drugs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>59 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laila ElAhwal, MD</last_name>
    <phone>00201018484319</phone>
    <email>lailaalahwal@gmail.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Laila Elahwal</investigator_full_name>
    <investigator_title>Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

